Peripheral artery disease (PAD) in lower extremities is very common and recognized as a worldwide health burden. Conventional risk factors such as smoking, hypertension, dyslipidemia and type 2 diabetes melllitus have a profound impact on the development and progression of PAD. Besides these risk factors, serum polyunsaturated fatty acids (PUFA) profile, measured as eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio (EPA/AA), has been drawing increasing attention as a novel risk factor for atherosclerosis. EPA has unique and diverse anti-inflammatory, antiplatelet, and anti-oxidant effects, with a variety of cardiovascular and endothelial protective actions. Serum PUFA profile may serve as a simple and valuable risk prediction tool to screen the asymptomatic patients for atherosclerotic disease, including PAD. This chapter emphasizes the importance of serum PUFA profile in our Japanese patient population with femoropopliteal or infrapopliteal PAD requiring percutaneous endovascular therapy. Despite the evidence about the impact of EPA/AA ratio on PAD, the therapeutic effects of intensive purified EPA supplementation on prevention and regression of PAD are conflicting and warrant future large-scale prospective studies and randomized trials.
|Title of host publication||Peripheral Artery Disease (PAD)|
|Subtitle of host publication||Risk Factors, Diagnosis and Emerging Treatments|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||16|
|Publication status||Published - Jan 1 2016|
All Science Journal Classification (ASJC) codes